相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
et al.
JOURNAL OF HEPATOLOGY (2015)
Pharmacodynamic change in plasma angiogenic proteins: a dose-escalation phase 1 study of the multi-kinase inhibitor lenvatinib
Noriyuki Koyama et al.
BMC CANCER (2014)
Changes in Plasma Vascular Endothelial Growth Factor at 8 Weeks After Sorafenib Administration as Predictors of Survival for Advanced Hepatocellular Carcinoma
Kaoru Tsuchiya et al.
CANCER (2014)
Hepatocellular Carcinoma: Reasons for Phase III Failure and Novel Perspectives on Trial Design
Josep M. Llovet et al.
CLINICAL CANCER RESEARCH (2014)
Brivanib as Adjuvant Therapy to Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma: A Randomized Phase III Trial
Masatoshi Kudo et al.
HEPATOLOGY (2014)
Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib The EVOLVE-1 Randomized Clinical Trial
Andrew X. Zhu et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
LIVER CANCER IN 2013 Mutational landscape of HCC-the end of the beginning
Augusto Villanueva et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2014)
Human and Mouse VEGFA-Amplified Hepatocellular Carcinomas Are Highly Sensitive to Sorafenib Treatment
Elad Horwitz et al.
CANCER DISCOVERY (2014)
A Phase II and Biomarker Study of Ramucirumab, a Human Monoclonal Antibody Targeting the VEGF Receptor-2, as First-Line Monotherapy in Patients with Advanced Hepatocellular Cancer
Andrew X. Zhu et al.
CLINICAL CANCER RESEARCH (2013)
Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: Multicentre, open-label, phase II safety study
Jordi Bruix et al.
EUROPEAN JOURNAL OF CANCER (2013)
FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma
Tokuzo Arao et al.
HEPATOLOGY (2013)
B-crystallin complexes with 14-3-3 to induce epithelial-mesenchymal transition and resistance to sorafenib in hepatocellular carcinoma
Xiao-Yong Huang et al.
HEPATOLOGY (2013)
Clinical impact of c-Met expression and its gene amplification in hepatocellular carcinoma
Shunsuke Kondo et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2013)
Phase III trial of linifanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC)
Calin Cainap et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
Philip J. Johnson et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study
Josep M. Llovet et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial
Ann-Lii Cheng et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
The antiangiogenic ceiling in hepatocellular carcinoma: does it exist and has it been reached?
Ghassan K. Abou-Alfa et al.
LANCET ONCOLOGY (2013)
Activation of JNK and high expression level of CD133 predict a poor response to sorafenib in hepatocellular carcinoma
S. Hagiwara et al.
BRITISH JOURNAL OF CANCER (2012)
A study of circulating interleukin 10 in prognostication of unresectable hepatocellular carcinoma
Stephen L. Chan et al.
CANCER (2012)
A Phase I Dose-Escalation Study of Regorafenib (BAY 73-4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid Tumors
Klaus Mross et al.
CLINICAL CANCER RESEARCH (2012)
Epidemiology of Viral Hepatitis and Hepatocellular Carcinoma
Hashem B. El-Serag
GASTROENTEROLOGY (2012)
Applicability of BCLC stage for prognostic stratification in comparison with other staging systems: single centre experience from long-term clinical outcomes of 1717 treatment-naive patients with hepatocellular carcinoma
Beom Kyung Kim et al.
LIVER INTERNATIONAL (2012)
Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma
Cecile Guichard et al.
NATURE GENETICS (2012)
Liver Resection and Transplantation in Hepatocellular Carcinoma
J. Belghiti et al.
LIVER CANCER (2012)
A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma
Fumihiko Kanai et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
Des-gamma-Carboxyprothrombin May Be a Promising Biomarker to Determine the Therapeutic Efficacy of Sorafenib for Hepatocellular Carcinoma
Kazuomi Ueshima et al.
DIGESTIVE DISEASES (2011)
Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma
Masatoshi Kudo et al.
EUROPEAN JOURNAL OF CANCER (2011)
Predicting the treatment effect of sorafenib using serum angiogenesis markers in patients with hepatocellular carcinoma
Koji Miyahara et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2011)
Early Clinical Development of ARQ 197, a Selective, Non-ATP-Competitive Inhibitor Targeting MET Tyrosine Kinase for the Treatment of Advanced Cancers
Alex A. Adjei et al.
ONCOLOGIST (2011)
The Significance of Early Alpha-Fetoprotein Level Changes in Predicting Clinical and Survival Benefits in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib
Thomas Yau et al.
ONCOLOGIST (2011)
Early Decrease in alpha-Fetoprotein, but Not Des-gamma-Carboxy Prothrombin, Predicts Sorafenib Efficacy in Patients with Advanced Hepatocellular Carcinoma
Teiji Kuzuya et al.
ONCOLOGY (2011)
Targeting the HGF/c-Met Axis: State of Play
Timothy A. Yap et al.
MOLECULAR CANCER THERAPEUTICS (2010)
The role of signaling pathways in the development and treatment of hepatocellular carcinoma
S. Whittaker et al.
ONCOGENE (2010)
Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis
S. J. Schoenleber et al.
BRITISH JOURNAL OF CANCER (2009)
PDGF-C Mediates the Angiogenic and Tumorigenic Properties of Fibroblasts Associated with Tumors Refractory to Anti-VEGF Treatment
Yongping Crawford et al.
CANCER CELL (2009)
Role of Overexpression of CD151 and/or c-Met in Predicting Prognosis of Hepatocellular Carcinoma
Ai-Wu Ke et al.
HEPATOLOGY (2009)
Angiogenesis in liver disease
Mercedes Fernandez et al.
JOURNAL OF HEPATOLOGY (2009)
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
Ann-Lii Cheng et al.
LANCET ONCOLOGY (2009)
The hepatocyte growth factor/c-Met signaling pathway as a therapeutic target to inhibit angiogenesis
Weon-Kyoo You et al.
BMB REPORTS (2008)
Novel advancements in the management of hepatocellular carcinoma in 2008
Josep M. Llovet et al.
JOURNAL OF HEPATOLOGY (2008)
Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection
Klaus Juergen Schmitz et al.
JOURNAL OF HEPATOLOGY (2008)
Angiogenesis selectively requires the p110α isoform of PI3K to control endothelial cell migration
Mariona Graupera et al.
NATURE (2008)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Bcl-2 protects endothelial cells against γ-radiation via a Raf-MEK-ERK-survivin signaling pathway that is independent of cytochrome c release
Pawan Kumar et al.
CANCER RESEARCH (2007)
Fibroblast growth factor-2-induced host stroma reaction during initial tumor growth promotes progression of mouse melanoma via vascular endothelial growth factor A-dependent neovascularization
Satoshi Tsunoda et al.
CANCER SCIENCE (2007)
Phase II study of sorafenib in patients with advanced hepatocellular carcinoma
Ghassan K. Abou-Alfa et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Raf: A strategic target for therapeutic development against cancer
M Beeram et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Intrahepatic gene expression profiles and alpha-smooth muscle actin patterns in hepatitis C virus induced fibrosis
DTY Lau et al.
HEPATOLOGY (2005)
Platelet-derived growth factor C induces liver fibrosis, steatosis, and hepatocellular carcinoma
JS Campbell et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Angiopoietin switching regulates angiogenesis and progression of human hepatocellular carcinoma
K Sugimachi et al.
JOURNAL OF CLINICAL PATHOLOGY (2003)
The phosphatidylinositol 3-kinase-AKT pathway in human cancer
I Vivanco et al.
NATURE REVIEWS CANCER (2002)
分享论文
